Business
NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference
Biomarkers show potential efficacyPrimeC is currently being evaluated for the treatment of ALS in a Phase 2b study with topline results expected in H2
About this update from Neurosense Therapeutics Ltd.
[{"type":"text","content":"Biomarkers show potential efficacyPrimeC is currently being evaluated for the treatment of ALS in a Phase 2b study with topline results expected in H2 2023Phase 2 double-blind proof-of-concept AD study is expected to commence in H1 2023CAMBRIDGE, Mass., March 23, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (\"NeuroSense\"), a company developing treatments for severe neurodegenerative diseases, today announced its Vice President of R&D, Dr. Shiran Zimri, will deliver two presentations at the AD/PD™ 2023 Advances in Science & Therapy Conference which takes place March 28 - April 1, 2023 in Gothenburg, Sweden.\n \nAmyotrophic Lateral Sclerosis (ALS) Lecture\nTitle: Shifting the paradigm–PrimeC: A potential disease modifying treatment for neurodegenerative disorders driven by novel biomarkers measuring mechanism of action\nFindings: PrimeC has demonstrated efficacy in pre-clinical models of ALS and was shown to be safe and tolerable in a Phase 2a clinical trial, with clinical signals of efficacy and significant changes revealed in ALS-related biomarkers. The synergistic mode of action of PrimeC as a combination therapy in ALS was measured in ALS-related biomarkers in neuronal derived exosomes (NDEs). Significant differences in ALS-related biomarkers were detected in people with ALS when compared to controls. Biomarkers related to inflammation, miRNA regulation, autophagy, and lysosomal trafficking were evaluated. Significant changes were observed in key ALS-related biomarkers following treatment with PrimeC.\nPrimeC is currently being evaluated for the treatment of ALS in a Phase 2b study. Topline results are expected in H2 2023. \nAlzheimer's Disease (AD) Poster\nTitle: Combination of ciprofloxacin/celecoxib as a Novel Therapeutic Strategy for Alzheimer's Disease\nFindings: In order to assess and characterize the relevance of NeuroSense's combination therapy (ciprofloxacin and celecoxib) as a potential treatment for AD, a biomarker discovery study was conducted utilizing NDEs extracted from the plasma of people living with AD vs neurologically healthy controls. Hallmarks of AD were detected, such as increased levels of amyloid β 42, tau phosphorylation, and TDP-43 in people living with AD, when compared to the healthy control group. Elevated levels of TDP-43 suggest potential efficacy of NeuroSense's combinatio...